

**Wanbury Limited**

Regd. Office: BSEL Tech Park, B-Wing, 10th Floor, Sector-30A, Opp. Vashi Railway Station, Vashi, Navi Mumbai 400703 Maharashtra, INDIA
Tel: +91-22-6794 2222
+91-22-7196 3222
CIN: L51900MH1988PLC048455
Email: info@wanbury.com
Website: www.wanbury.com

October 16, 2026

BSE Limited PJ. Towers, Dalal Street Mumbai – 400 001. Script Code: 524212	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai -400 051. Script Code: WANBURY
---	---

Dear Sir/Madam,

Sub.: Wanbury Limited – Regulatory Progress in API Business, New Business Opportunities and Operational Achievements

Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under:

Please find enclosed the press release highlighting the Company's regulatory progress in its API business, expansion of its product pipeline and new business opportunities in Saudi Arabia and Mexico.

This is for your information and records.

Thanking you.

**Yours faithfully,
For Wanbury Limited**

JITENDRA
JAYANTILAL
GANDHI

Digitally signed by JITENDRA JAYANTILAL GANDHI
DN: cn=JITENDRA JAYANTILAL GANDHI, o=Wanbury Limited, ou=JITENDRA JAYANTILAL GANDHI, email=jgandhi@wanbury.com, c=IN
c=IN, o=Wanbury Limited, ou=JITENDRA JAYANTILAL GANDHI, email=jgandhi@wanbury.com
Date: 2024.10.16 12:41:51 +05'30'

**Jitendra J. Gandhi
Company Secretary**

Encl.: a/a



PRESS RELEASE

Key Updates and Developments

Wanbury Receives 9 “No DMF Deficiency” Letters from USFDA for Metformin HCl, Expands Metformin Business in Saudi Arabia and Mexico

Mumbai, 16th Oct 2026: Wanbury Limited today shared key updates across regulatory approvals, its API pipeline, new Metformin business and recognition for its manufacturing sites.

Regulatory milestones: “No DMF Deficiency” letters from USFDA

During July–August 2026, Wanbury received 9 “No DMF Deficiency” letters from the USFDA for its Metformin HCl Drug Master File (DMF). These letters were issued as part of the USFDA’s review of Abbreviated New Drug Applications (ANDAs) filed by Wanbury’s customers.

In the same period, the company also received “No DMF Deficiency” letters for two more APIs: Paroxetine and Diphenhydramine HCl. These outcomes reaffirm the quality of Wanbury’s regulatory filings and open up new business opportunities with customers in the regulated US market.

Strengthening the API pipeline

Wanbury is expanding its API portfolio by validating new products, including Quetiapine Fumarate, Sitagliptin and Empagliflozin. Regulatory filings for these products are planned in next quarter. The APIs are expected to be available for sale in semi-regulated markets, adding to the company’s growth avenues.

Business growth: Saudi Arabia and Mexico

- **Saudi Arabia:** Wanbury has commercialised a new Metformin DC (directly compressible) business in Saudi Arabia, with an annual revenue potential of about Rs 10 crore.
- **Mexico:** Wanbury’s customer in Mexico has won a two-year tender for the supply of Metformin. The tender is valued at approximately Rs 15 crore per annum.

Together, these opportunities strengthen Wanbury’s position as a leading global supplier of Metformin.



Commenting on the developments, Mr. Mohan Rayana, Director of Wanbury Limited said,

“The ‘No DMF Deficiency’ letters from the USFDA are a strong endorsement of our quality and regulatory capabilities. With new Metformin business in Saudi Arabia and Mexico, and new APIs such as Quetiapine Fumarate, Sitagliptin and Empagliflozin in our pipeline, we are well placed for sustained growth”.

About Wanbury Ltd:

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes Antidiabetic, Antidepressant, Pain management, Antihistamine, Anti-inflammatory, Antidepressant and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory, & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For any Investor Relations query, please contact:

Jitendra J. Gandhi Company Secretary, Wanbury Limited BSEL Techpark,B' Wing, 10th Floor, Sector 30-A,Opp. Vashi Railway Station, Vashi, Navi Mumbai - 400703, Maharashtra, India. Tel: +91-22-6794 2222 Email: jitendra.gandhi@wanbury.com	Smit Shah / Hanishi Shah Adfactors PR Oasis Complex, Kamala Mills Compound, City Hall, Pandurang Budhkar Marg, Lower Parel West, Mumbai - 400021 Tel : +91 9870789596 / +91 9619059339 Email : smit.shah@adfactorspr.com / hanishi.shah@adfactorspr.com
--	---

Caution Concerning Forward- Looking Statements:

This document may contain statements, which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.